Metabolic dysfunction-associated steatotic liver disease (formerly NAFLD/NASH), MASH, and liver-directed metabolic therapy.
An exploratory analysis within the FLIPAN trial links larger liver-fat reductions on a Mediterranean diet to mixed environmental signals, with only higher water use surviving adjustment. PICO summary and expert commentary.
A three-arm RCT shows 24 g/day dietary fibre improves HbA1c and the FIB-4 fibrosis marker in type 2 diabetes with MASLD. PICO summary and expert commentary for clinicians.
A 12-month RCT finds curcumin 1500 mg daily reduces liver fat, stiffness, and HbA1c in obese type 2 diabetes with MASLD. PICO summary and expert commentary for clinicians.
A multicentre RCT finds berberine 1 g/day for 6 months does not reduce visceral or liver fat in obesity with fatty liver disease, though it modestly lowers LDL, apoB, and hs-CRP. PICO summary and commentary.
The NAFLDiet trial finds both a low-carb high-PUFA diet and a healthy Nordic diet reduce liver fat versus usual care, but only the Nordic diet also improves weight, HbA1c, triglycerides, and inflammation. PICO summary and commentary.
The phase 2b IMPACT trial finds weekly pemvidutide resolves MASH but does not significantly improve fibrosis at 24 weeks. PICO summary and expert commentary.
A 12-week trial finds aerobic, Tabata, and HIIT all reduce body fat and circulating hepatokines in obese men, with higher-intensity protocols producing the greatest reductions. PICO summary and commentary.
A first-in-human phase 1 study finds the FGF21 analog zalfermin supports weekly dosing and improves lipids in healthy men. PICO summary and expert commentary.
A 12-month RCT finds daily curcumin reduces liver fat, stiffness, and HbA1c and improves inflammatory and antioxidant markers in obese type 2 diabetes with fatty liver. PICO summary and commentary.
An RCT finds adding ezetimibe to metformin raises PPAR-gamma and adiponectin expression and improves insulin resistance in diabetic fatty liver disease, though endpoints are surrogate. PICO summary and commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
